IL88513A - D5-1-]) 2-benzyl-3,4-dihydro-H-2 benzopyran-6-yl (methyl [thiazolidine-2,4-deion as a medicinal preparation against atherosclerosis - Google Patents

D5-1-]) 2-benzyl-3,4-dihydro-H-2 benzopyran-6-yl (methyl [thiazolidine-2,4-deion as a medicinal preparation against atherosclerosis

Info

Publication number: IL88513A
Authority: IL; Israel
Prior art keywords: compound; formula; dione; thiazolidine; pharmaceutically acceptable
Prior art date: 1987-12-02

Application number

IL8851388A

Other languages

English (en)

Hebrew (he)

Other versions

IL88513A0 (en

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-12-02

Filing date

1988-11-28

Publication date

1994-04-12

1988-11-28 Application filed by Pfizer filed Critical Pfizer

1989-06-30 Publication of IL88513A0 publication Critical patent/IL88513A0/xx

1994-04-12 Publication of IL88513A publication Critical patent/IL88513A/en

Links

239000008194 pharmaceutical composition Substances 0.000 title claims description 8
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 title abstract description 12
-1 2-benzyl-3,4- dihydro-2h-benzopyran-6- yl Chemical group 0.000 title abstract description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title abstract description 5
230000000879 anti-atherosclerotic effect Effects 0.000 title description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 47
125000002091 cationic group Chemical group 0.000 claims abstract description 14
241000124008 Mammalia Species 0.000 claims abstract description 11
150000001875 compounds Chemical class 0.000 claims description 44
159000000000 sodium salts Chemical class 0.000 claims description 4
238000007911 parenteral administration Methods 0.000 claims description 2
210000002966 serum Anatomy 0.000 claims description 2
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
200000000007 Arterial disease Diseases 0.000 abstract description 2
238000000034 method Methods 0.000 abstract description 2
230000000979 retarding effect Effects 0.000 abstract description 2
235000012000 cholesterol Nutrition 0.000 description 11
241001465754 Metazoa Species 0.000 description 9
241000282472 Canis lupus familiaris Species 0.000 description 7
208000024172 Cardiovascular disease Diseases 0.000 description 7
150000003839 salts Chemical class 0.000 description 7
201000001320 Atherosclerosis Diseases 0.000 description 6
208000031226 Hyperlipidaemia Diseases 0.000 description 6
150000002632 lipids Chemical class 0.000 description 6
235000005911 diet Nutrition 0.000 description 5
230000037213 diet Effects 0.000 description 5
229920000609 methyl cellulose Polymers 0.000 description 5
239000001923 methylcellulose Substances 0.000 description 5
235000010981 methylcellulose Nutrition 0.000 description 5
239000000243 solution Substances 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
108010007622 LDL Lipoproteins Proteins 0.000 description 4
102000007330 LDL Lipoproteins Human genes 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
239000003814 drug Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
108010062497 VLDL Lipoproteins Proteins 0.000 description 3
239000003472 antidiabetic agent Substances 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
229940126904 hypoglycaemic agent Drugs 0.000 description 3
239000000203 mixture Substances 0.000 description 3
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
108010028554 LDL Cholesterol Proteins 0.000 description 2
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
108010069201 VLDL Cholesterol Proteins 0.000 description 2
210000000709 aorta Anatomy 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
244000144993 groups of animals Species 0.000 description 2
230000003902 lesion Effects 0.000 description 2
210000000329 smooth muscle myocyte Anatomy 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 description 1
208000031104 Arterial Occlusive disease Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
239000004380 Cholic acid Substances 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000016942 Elastin Human genes 0.000 description 1
108010014258 Elastin Proteins 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000002705 Glucose Intolerance Diseases 0.000 description 1
206010018429 Glucose tolerance impaired Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
241000220317 Rosa Species 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
208000021328 arterial occlusion Diseases 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
238000012925 biological evaluation Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
210000001627 cerebral artery Anatomy 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
235000019416 cholic acid Nutrition 0.000 description 1
229960002471 cholic acid Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
235000021196 dietary intervention Nutrition 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
229940043237 diethanolamine Drugs 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
229920002549 elastin Polymers 0.000 description 1
229940012017 ethylenediamine Drugs 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
201000001421 hyperglycemia Diseases 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
229960003194 meglumine Drugs 0.000 description 1
WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
238000003305 oral gavage Methods 0.000 description 1
239000001301 oxygen Chemical group 0.000 description 1
229910052760 oxygen Chemical group 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
235000019371 penicillin G benzathine Nutrition 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
229960000281 trometamol Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

IL8851388A 1987-12-02 1988-11-28 D5-1-]) 2-benzyl-3,4-dihydro-H-2 benzopyran-6-yl (methyl [thiazolidine-2,4-deion as a medicinal preparation against atherosclerosis IL88513A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/127,858 US4798835A (en)	1987-12-02	1987-12-02	dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent

Publications (2)

Publication Number	Publication Date
IL88513A0 IL88513A0 (en)	1989-06-30
IL88513A true IL88513A (en)	1994-04-12

Family

ID=22432331

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL8851388A IL88513A (en)	1987-12-02	1988-11-28	D5-1-]) 2-benzyl-3,4-dihydro-H-2 benzopyran-6-yl (methyl [thiazolidine-2,4-deion as a medicinal preparation against atherosclerosis

Country Status (16)

Country	Link
US (1)	US4798835A (de)
EP (1)	EP0319288B1 (de)
JP (1)	JPH01186883A (de)
KR (1)	KR900006993B1 (de)
AT (1)	ATE81456T1 (de)
AU (1)	AU604176B2 (de)
CA (1)	CA1313139C (de)
DE (1)	DE3875324T2 (de)
DK (1)	DK670988A (de)
HU (1)	HU204433B (de)
IE (1)	IE883600L (de)
IL (1)	IL88513A (de)
MY (1)	MY103498A (de)
PH (1)	PH24873A (de)
PT (1)	PT89123B (de)
ZA (1)	ZA888968B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5053420A (en) *	1989-10-13	1991-10-01	Pershadsingh Harrihar A	Thiazolidine derivatives for the treatment of hypertension
ES2092539T3 (es) *	1991-01-10	1996-12-01	Transcend Therapeutics Inc	Uso de derivados de la tiazolidina-4-carboxilato para el tratamiento de enfermedades pulmonares.
US5747459A (en) *	1991-02-04	1998-05-05	Nestec, Ltd.	Method for insuring adequate intracellular glutathione in tissue
US5866595A (en) *	1991-09-26	1999-02-02	The Regents Of The University Of California	Calcium antagonists for treatment of vascular restenosis
US5430045A (en) *	1992-04-23	1995-07-04	Free Radical Sciences, Inc.	Method of reducing or preventing bone marrow hypoplasia
US5306724A (en) *	1992-08-17	1994-04-26	Clintec Nutrition Company	Method for preventing and treating atherosclerosis
US5447712A (en) *	1993-12-09	1995-09-05	Free Radical Sciences	Method of reducing cyclophosphamide induced hemorrhagic cystitis
GB9611947D0 (en) *	1996-06-07	1996-08-07	Glaxo Group Ltd	Medicaments

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5522636A (en) *	1978-08-04	1980-02-18	Takeda Chem Ind Ltd	Thiazoliding derivative
JPS58118577A (ja) *	1982-01-07	1983-07-14	Takeda Chem Ind Ltd	チアゾリジン誘導体
US4617312A (en) *	1983-01-17	1986-10-14	Pfizer Inc.	Aldose reductase inhibiting 5-(2-alkoxyphenyl) thiazolidinediones
JPS6051189A (ja) *	1983-08-30	1985-03-22	Sankyo Co Ltd	チアゾリジン誘導体およびその製造法
AR240698A1 (es) *	1985-01-19	1990-09-28	Takeda Chemical Industries Ltd	Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
HU210339B (en) *	1985-05-21	1995-03-28	Pfizer	Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
JPH06779B2 (ja) *	1985-06-10	1994-01-05	武田薬品工業株式会社	チアゾリジオン誘導体およびそれを含んでなる医薬組成物

1987
- 1987-12-02 US US07/127,858 patent/US4798835A/en not_active Expired - Lifetime
1988
- 1988-11-26 MY MYPI88001364A patent/MY103498A/en unknown
- 1988-11-28 IL IL8851388A patent/IL88513A/en unknown
- 1988-11-29 JP JP63302127A patent/JPH01186883A/ja active Granted
- 1988-11-30 PT PT89123A patent/PT89123B/pt not_active IP Right Cessation
- 1988-11-30 ZA ZA888968A patent/ZA888968B/xx unknown
- 1988-11-30 CA CA000584530A patent/CA1313139C/en not_active Expired - Fee Related
- 1988-12-01 EP EP88311378A patent/EP0319288B1/de not_active Expired - Lifetime
- 1988-12-01 DK DK670988A patent/DK670988A/da not_active Application Discontinuation
- 1988-12-01 HU HU886143A patent/HU204433B/hu not_active IP Right Cessation
- 1988-12-01 AT AT88311378T patent/ATE81456T1/de not_active IP Right Cessation
- 1988-12-01 AU AU26471/88A patent/AU604176B2/en not_active Ceased
- 1988-12-01 IE IE883600A patent/IE883600L/xx unknown
- 1988-12-01 DE DE8888311378T patent/DE3875324T2/de not_active Expired - Fee Related
- 1988-12-01 KR KR1019880015992A patent/KR900006993B1/ko not_active Expired
- 1988-12-02 PH PH37884A patent/PH24873A/en unknown

Also Published As

Publication number	Publication date
ATE81456T1 (de)	1992-10-15
IL88513A0 (en)	1989-06-30
PT89123A (pt)	1989-12-29
IE883600L (en)	1989-06-02
US4798835A (en)	1989-01-17
DE3875324T2 (de)	1993-02-25
AU604176B2 (en)	1990-12-06
HUT54045A (en)	1991-01-28
AU2647188A (en)	1989-06-08
CA1313139C (en)	1993-01-26
PT89123B (pt)	1993-09-30
DK670988D0 (da)	1988-12-01
EP0319288A3 (en)	1990-12-27
JPH01186883A (ja)	1989-07-26
ZA888968B (en)	1990-07-25
DK670988A (da)	1989-07-24
JPH0460582B2 (de)	1992-09-28
DE3875324D1 (de)	1992-11-19
EP0319288A2 (de)	1989-06-07
PH24873A (en)	1990-12-26
MY103498A (en)	1993-06-30
EP0319288B1 (de)	1992-10-14
HU204433B (en)	1992-01-28
KR900006993B1 (ko)	1990-09-25
KR890009922A (ko)	1989-08-04

Publication	Publication Date	Title
JP2004210797A (ja)	2004-07-29	アムロジピン及びアトルバスタチンを含む治療用の組み合わせ
HU220669B1 (hu)	2002-04-29	Eljárás diabéteszes szövődmények kezelésére vagy megelőzésére szolgáló gyógyászati készítmények előállítására
FR2774591A1 (fr)	1999-08-13	Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
US4798835A (en)	1989-01-17	dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent
CN1092517C (zh)	2002-10-16	利用2,6－二烷基－4－甲硅烷基－苯酚降低血清胆固醇水平的方法
FR2590170A1 (fr)	1987-05-22	Agents therapeutiques a base de sel d'acyloxyalcanoylcholine, apportant une amelioration dans le traitement de la demence
US5739159A (en)	1998-04-14	Medicaments for the treatment of cardiac insufficiency
US20040009986A1 (en)	2004-01-15	Triglyceride depressant composition
CA2088582A1 (en)	1992-12-08	Anti-diabetes mellitus
CA2123059C (en)	1997-01-21	Method of lowering blood lipid levels
US6440951B1 (en)	2002-08-27	Method for treatment of diabetes
US6998422B2 (en)	2006-02-14	Lipid peroxide-lowering compositions
EP0545805A1 (de)	1993-06-09	Verwendung von D-Fenfluramin und Fenfluraminderivaten zur Behandlung von hypertonischen Patienten mit Insulin-Resistenz
US5175179A (en)	1992-12-29	Method for treating hypertension
EP0469837B1 (de)	1994-11-09	Verwendung einer Verbindung zur Herstellung eines Arzneimittels zur Senkung des Harnsäuregehalts des Blutes
US6479676B1 (en)	2002-11-12	OxiranEcarboxylic acids for the treatment of diabetes
US4847255A (en)	1989-07-11	Cyclopentyl ethers and their use in medicine
AU651873B2 (en)	1994-08-04	Method of inhibiting the progressive development of diabetes mellitus
US4978667A (en)	1990-12-18	Substituted 6H-7,8-dihydrothiapyrano(3,2-d)-pyrimidines as hypoglycemic agents
KR920003579B1 (ko)	1992-05-04	혈중 지질 조성을 개선시키기 위한 제약 조성물
MXPA00002085A (en)	2001-03-05	Combination therapy comprising amlodipine and a statin compound